Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Escitalopram Tablet (20 mg) relative to Lexapro in healthy Thai volunteers under fasting conditions
TCTR20190523001Phase 1Not yet recruiting
- Sponsor
- Pond Chemical
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of escitalopram in major depressive disorder (MDD) and generalized anxiety disorder (GAD) (2 arms), sponsored by Pond Chemical. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on TCTR20190523001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190523001.